CLAIMS

1. Use of at least one vasopressin receptor antagonist or mixtures of such antagonists for the treatment of disturbances or illnesses of the inner ear.

2. Use according to claim 1, characterized in that the receptor antagonist is a vasopressin-V_2-receptor antagonist.

3. Use according to claim 1 or 2, characterized in that the disturbance or illness of the inner ear is associated with at least one of the symptoms vertigo, impairment of hearing or tinnitus.

4. Use according to claim 3, characterized in that the impairment of hearing is a deep sound hearing impairment.

5. Use according to one of the preceding claims, characterized in that the disturbance or illness of the inner ear is linked with a hydrops, particularly an endolymphatic hydrops.

6. Use according to one of the preceding claims, characterized in that the disturbance or illness of the inner ear is Menière's disease.

7. Use according to one of the preceding claims, characterized in that the receptor antagonist is a peptide compound.

8. Use according to claim 7, characterized in that the peptide compound is a linear peptide, particularly propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-NH_2.

9. Use according to one of the claims 1 to 6, characterized in that the receptor antagonist is a non-peptidic, preferably non-peptidic, organic substance.

10. Use according to claim 9, characterized in that the organic substance is a benzazepin derivative.

11. Use according to claim 10, characterized in that the benzazepin derivative is 5-dimethylamino-1-{4-(2-methyl-benzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin.

12. Use according to claim 9, characterized in that the organic substance is an indole derivative.

13. Use according to claim 12, characterized in that the indole derivative is 1-[4-(N-tert.-butyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-indol-2-one fumarate.

14. Use according to one of the preceding claims, characterized in that the receptor antagonist can be administered orally and/or intravenously, particularly orally.

15. Use according to one of the preceding claims, characterized in that the receptor antagonist is used in a quantity of 0.1 to 50 mg/kg of body weight and per day.

16. Use according to one of the preceding claims, characterized in that the receptor antagonist is contained in a formulation or medicament intended for administration in a quantity of 1 to 75 wt.%, preferably 5 to 50 wt.%, preferably 5 to 25 wt.%.

17. Process for the treatment of disturbances or illnesses of the inner ear, characterized in that at least one vasopressin receptor antagonist or mixtures of such antagonists is administered in a suitable, compatible quantity.

18. Process according to claim 17, characterized by at least one of the features of claims 2 to 16.

19. Pharmaceutical composition or medicament for the treatment of disturbances or illnesses of the inner ear, characterized in that at least one vasopressin receptor antagonist or mixtures of such antagonists is contained.

20. Composition or medicament according to claim 19, characterized by at least one of the features of claims 7 to 16.